Hims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume on Analyst Upgrade

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually-strong trading volume on Tuesday after Citigroup upgraded the stock from a sell rating to a neutral rating. Citigroup now has a $24.00 price target on the stock, up from their previous price target of $13.25. Approximately 49,826,566 shares traded hands during trading, an increase of 59% from the previous session’s volume of 31,374,480 shares.The stock last traded at $22.9990 and had previously closed at $22.16.

Other research analysts have also recently issued reports about the stock. Barclays decreased their price objective on shares of Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 24th. BTIG Research lowered Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Monday. Leerink Partners cut their price target on shares of Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating on the stock in a report on Tuesday, February 24th. Finally, TD Cowen reduced their target price on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $30.46.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,463 shares of company stock valued at $2,846,696 in the last quarter. Insiders own 17.71% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk deal and end of lawsuit — reports say Novo will distribute Wegovy/Ozempic through Hims, ending the legal feud and removing a major overhang that triggered the recent selloff. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Market coverage and headlines amplified the move — multiple outlets reported big pre‑market gains and characterized the pact as a strategic pivot that could materially improve HIMS’ GLP‑1 offering. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud
• Positive Sentiment: Analyst upgrades and higher price targets — Needham bumped HIMS to Buy ($30 PT), Citigroup moved from Sell to Neutral ($24 PT), Deutsche Bank raised its PT to $28, and BofA moved to Neutral; these changes support the stock’s momentum. TickerReport (Citigroup upgrade)
• Neutral Sentiment: Zacks and other outlets note HIMS is a trending/watched stock — increased retail and institutional attention can amplify moves but also increase volatility. Hims & Hers Health, Inc. (HIMS) Is a Trending Stock
• Neutral Sentiment: Analyses highlight the strategic pivot — coverage (Finbold/Investopedia/etc.) frames the deal as a potential long‑term positive for margins and product mix, but outcomes depend on execution and pricing. Is HIMS stock the best buy in March 2026?
• Negative Sentiment: Shareholder investigation — Kahn Swick & Foti announced an inquiry into the company’s officers and directors, which could lead to litigation or governance scrutiny. Hims & Hers Health Investigation Initiated
• Negative Sentiment: Short‑squeeze and sustainability warnings — several analysts and media outlets flag heavy short interest and the risk that a rapid squeeze could reverse sharply, making gains potentially volatile and unsustainable. Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade)

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in Hims & Hers Health in the second quarter worth about $26,000. Quent Capital LLC acquired a new position in Hims & Hers Health during the 3rd quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter worth $28,000. Finally, Bogart Wealth LLC grew its stake in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 4.1%

The company has a market cap of $5.26 billion, a price-to-earnings ratio of 45.15, a P/E/G ratio of 3.01 and a beta of 2.56. The company’s fifty day moving average is $24.51 and its two-hundred day moving average is $37.89. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same quarter last year, the business earned $0.11 earnings per share. The firm’s revenue was up 28.4% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has authorized a share buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.